.avif)
Quotient Sciences Email Format
Pharmaceutical Manufacturing
・
1,001-2,500 employees
・
Nottingham, England, UK
Quotient Sciences is a pharmaceutical drug development and manufacturing accelerator providing integrated programs across the entire development pathway from facilities in the US and UK.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@quotientsciences.com
Company Overview
Industry
Pharmaceutical Manufacturing
Headquarters
Nottingham, England, UK
Revenue
$1B-$2.5B
FUNDING Stage
Private
Website
Key Executives
Thierry Van Nieuwenhove (Chief Executive Officer), Des Glass (Executive Vice President & Chief Financial Officer), Denise Sutton (COO - TP & Clinical Services)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Quotient Sciences?
Quotient Sciences uses the first.last format, so Jane Smith would be jane.smith@quotientsciences.com.
What is Quotient Sciences' Translational Pharmaceutics platform and how does it speed up drug development?
Translational Pharmaceutics is Quotient Sciences' proprietary integrated platform that combines formulation development, clinical manufacturing, and clinical testing into a single program, cutting development timelines by 12 months or more across more than 500 drug programs.
Which therapeutic areas does Quotient Sciences focus on?
Quotient Sciences focuses on oncology, orphan and rare diseases, CNS and neurology, and GI and gastroenterology, supporting pharmaceutical and biotech customers from candidate selection through to commercial manufacturing.
How can I find the right Quotient Sciences contact for an early clinical development partnership?
Tools like Clay can help you identify and verify the right Quotient Sciences contact by role or team, making it easier to reach the right person for an early clinical development or CRDMO partnership inquiry.
Did Quotient Sciences advance any AI-driven programs into clinical trials in 2026?
Yes, in May 2026 Quotient Sciences initiated a Phase I clinical study evaluating an AI-designed oral solid dose formulation in healthy volunteers at its UK facility, following MHRA approval, in what the company describes as a first-of-its-kind milestone.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating